Shots:

• CVS dropped Sanofi's Lantus drug from the list of medicines & reimburses on behalf of health insurers. The company reported that the number of changes to its formulary & helped private-sector medical insurers to negotiate better prices from drugmakers and also draw up formularies
• Novartis and Actelion were also dealt blows by CVS’s new formulary. Additionally- the patent on Lantus has expired in 2015 in the US- and Sanofi hopes to revive declining diabetes sales with Toujeo which launched in Mar’15
• Sanofi shares decreased to 1.4% at 1250 GMT- its last week sales were decreased to 3.5 % at constant exchange rates to $1.8B

Ref: Biogen | Image: Stat News